))
Neurology Edition: Top Headlines for Week of April 24, 2023
Manage episode 407442274 series 3560281
Content provided by Healio. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Healio or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
In this edition, trichloroethylene may be ‘invisible’ cause of PD, ravulizumab reduces clinical deterioration in generalized myasthenia gravis and more.
Read the full coverage here:
Trichloroethylene may be ‘invisible and highly preventable’ cause of Parkinson’s disease
DEA petitioned to de-schedule dual orexin receptor antagonist insomnia medications
Ravulizumab reduces clinical deterioration in patients with generalized myasthenia gravis
FDA places partial clinical hold on initiation of new patients in evobrutinib study
FDA advisory committees rule in favor of Rexulti for agitation associated with Alzheimer’s
References:
Dorsey ER, et al. J Parkinsons Dis. 2023;doi:10.3233?JPD-225047.
Mantegazza R, et al. Poster 148: Ravulizumab reduces clinical deteriorations in patients with generalized myasthenia gravis: Results from the CHAMPION MG study. Presented at: Muscular Dystrophy Association Clinical & Scientific Conference; March 19-22, 2023; Dallas.
108 episodes
Share
